Change the keyword or sentiment above, then click Apply.
Friday, 18 Sep 20261 update
↗ AI sentiment: Bullish
86% confidence
Manipal Health Enterprises: Redeems ₹5,310 Crore NCDs Using IPO Funds, Enhances Balance Sheet
Thursday, 10 Sep 20265 updates
↗ AI sentiment: Bullish
86% confidence
Manipal Hospitals: Jefferies on Manipal Hospitals initiates Buy, Target Price ₹870, citing excellence at scale with industry-leading metrics, a proven integration playbook, balanced brownfield/greenfield expansion, and operating leverage from scale and the Sahyadri turnaround
↗ AI sentiment: Bullish
77% confidence
Manipal: Goldman Sachs on Manipal Hospitals Buy, Target Price ₹865, as strong Karnataka/Bengal operations and Maharashtra expansion via Sahyadri support >20% FY26–29E revenue CAGR, while ex-Sahyadri EBITDA margins of 26.3% are expected to expand; strong acquisition track record and estimates above consensus support the view, with execution and competition as key risks.
↗ AI sentiment: Bullish
84% confidence
Manipal Hospitals: Goldman Sachs on Manipal Hospitals Initiate Buy, Target Price ₹865, expecting >20% topline CAGR and industry-leading core margins, supported by new-hospital ramp-up, better base-business mix, operating leverage and Manipal’s strong track record of turning around acquired hospitals.
↗ AI sentiment: Bullish
60% confidence
Manipal Hospitals: UBS on Manipal Hospitals Initiate Neutral, Target Price ₹850, expecting 19% revenue and 20% EBITDA CAGR FY26–30E, with upside from faster Sahyadri turnaround/new Bengaluru facilities, but lower ROIC and premium 28x forward EV/EBITDA limit further re-rating.
↗ AI sentiment: Bullish
86% confidence
Manipal Hospitals: JPMorgan on Manipal Hospitals Neutral, Target Price ₹800, as steady volumes, ARPOB growth, acquired-asset ramp-up and ~2,600 new beds support growth, but low-single-digit return ratios, Sahyadri integration and valuation at 27x/22x FY28/29 EV/EBITDA limit upside.
Friday, 28 Aug 20261 update
↗ AI sentiment: Bullish
89% confidence
HSBC Begins Buy Recommendation For Manipal Health With Target Price Set At ₹1,000, Expecting Profit Growth To Reach Nearly 3X From FY26-29E After Doubling Hospital Beds Since FY23, And Reducing Net Debt/EBITDA To 0.7X By FY27E From 3.7X, Highlighting Margin Improvements As A Significant Factor.
Thursday, 27 Aug 20261 update
↗ AI sentiment: Bullish
63% confidence
Manipal Health Enterprises: Co-CEO Plans For Growth Through Increased Volume, Enhanced Capacity, And Lower Debt.